Abstract
The serine/threonine protein kinase Akt, a downstream effector of phosphoinositide 3-kinase (PI3K), plays a pivotal role in tumorigenesis because it affects the growth and survival of cancer cells. Several laboratories have demonstrated that Akt inhibits transcriptional activation of a number of related forkhead transcription factors now referred to as FoxO1, FoxO3, and FoxO4. Akt-regulated forkhead transcription factors are involved in the control of the expression of both the cyclin-dependent kinase (cdk) inhibitor p27Kip1 and proapoptotic Bim protein. Very little information is available concerning the importance of the PI3K/Akt pathway in HL60 human leukemia cells. Here, we present our findings showing that the PI3K/Akt axis regulates cell cycle progression of HL60 cells through multiple mechanisms also involving the control of FoxO1 and FoxO3. To this end, we took advantage of a HL60 cell clone (HL60AR cells) with a constitutively activated PI3K/Akt axis. When compared with parental (PT) HL60 cells, HL60AR cells displayed higher levels of phosphorylated FoxO1 and FoxO3. In AR cells forkhead factors localized predominantly in the cytoplasm, whereas in PT cells they were mostly nuclear. AR cells proliferated faster than PT cells and showed a lower amount of the cdk inhibitor p27Kip1, which was mainly found in the cytoplasm and was hyperphosphorylated on threonine residues. AR cells also displayed higher levels of cyclin D1 and phosphorylated p110 Retinoblastoma protein. The protein levels of cdk2, cdk4, and cdk6 were not altered in HL60AR cells, whereas the activities of both ckd2 and cdk6 were higher in AR than in PT cells. These results show that in HL60 cells the PI3K/Akt signaling pathway may be involved in the control of the cell cycle progression most likely through mechanisms involving the activation of forkhead transcription factors.
Similar content being viewed by others
References
Testa JR, Bellacosa A . AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983–10985.
Nicholson KM, Anderson NG . The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002; 14: 381–395.
Cantrell DA . Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439–1445.
Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD . Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615–675.
Brazil DP, Hemmings BA . Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26: 657–664.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673–5683.
Du K, Montminy M . CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998; 273: 32377–32379.
Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE et al. Akt/protein kinase B up-regulates Bcl-2 expression through c-AMP-response element-binding protein. J Biol Chem 2000; 275: 10761–10766.
Rena G, Guo S, Cichy SC, Unterman TG, Cohen P . Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 1999; 274: 17179–17183.
Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC . Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 1999; 96: 7421–7426.
Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM . Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 1999; 398: 630–634.
Kaestner KH, Knochel W, Martinez DE . Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14: 142–146.
Brownawell AM, Kops GJPL, Macara IG, Burgering BMT . Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol Cell Biol 2001; 21: 3534–3546.
Stahl M, Dijkers PF, Kops GJPL, Lens SMA, Coffer PJ, Burgering BMT et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 2002; 168: 5024–5031.
Tazzari PL, Cappellini A, Bortul R, Ricci F, Billi AM, Tabellini G et al. Flow cytometric detection of total and serine 473 phosphorylated Akt. J Cell Biochem 2002; 86: 704–715.
Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G et al. The phosphoinositide 3-kinase/AKT1 pathway involvement in multidrug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234–246.
Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R et al. Constitutively active AKT1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and c-FLIPL up-regulation. Leukemia 2003; 17: 379–389.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
Ashkenazi A, Pai RC, Fong S, Lueng S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.
Neri LM, Borgatti P, Capitani S, Martelli AM . The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta 2002; 1584: 73–80.
Lawlor MA, Alessi DR . PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903–2910.
Toyoshima H, Hunter T . p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74.
Nakayama K, Nakayama K . Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. BioEssays 1998; 20: 1020–1029.
Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136–1144.
Kiang J, Zubovitz J, Petrocelli T, Kotchekov R, Connor MK, Han K et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153–1160.
Bell SP, Dutta A . DNA replication in eukaryotic cells. Annu Rev Biochem 2002; 71: 333–374.
Kops GJ, Burgering BM . Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 2000; 197: 571–574.
Burgering BM, Kops GJ . Cell cycle and death control: long live forkheads. Trends Biochem Sci 2002; 27: 352–360.
Coqueret O . New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13: 65–70.
Obaya AJ, Sedivy JM . Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002; 59: 126–142.
Ho A, Dowdy SF . Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 2002; 12: 47–52.
Smits VA, Medema RH . Checking out the G(2)/M transition. Biochim Biophys Acta 2001; 1519: 1–12.
Sherr CJ, Roberts JM . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–1512.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145–1152.
Blain SW, Massagué J . Breast cancer banishes p27 from nucleus. Nat Med 2002; 8: 1076–1078.
Stiegler P, Giordano A . The family of retinoblastoma proteins. Crit Rev Eukaryot Gene Expr 2001; 11: 59–76.
Wang QM, Jones JB, Studzinski GP . Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cell. Cancer Res 1996; 56: 264–267.
Wang QM, Luo X, Kheir A, Coffman FD, Studzinski GP . Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D3 display increased CDK2 and CDK6 activity and shortened G1 phase. Oncogene 1998; 16: 2729–2737.
Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 1999; 8: 185–193.
Aggerholm A, Grønbćaek K, Guldberg P, Hokland P . Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorder. Eur J Haematol 2000; 65: 109–113.
Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF . Mutational analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 2000; 63: 170–175.
Yamada KM, Araki M . Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001; 114: 2375–2382.
Luo J-M, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. Possibile dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1–8.
Krystal G, Damen JE, Helgason CD, Huber M, Hughes MR, Kalesnikoff J et al. SHIPs ahoy. Int J Biochem Cell Biol 1999; 31: 1007–1010.
G-Amlak M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun 2002; 297: 760–764.
Engstrom M, Karlsson R, Jonsson JI . Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. Exp Hematol 2003; 31: 316–323.
Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB . Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. Exp Hematol 2002; 30: 990–1000.
Komatsu N, Watanabe T, Uchida M, Mori M, Kirito K, Kikuchi S et al. A member of forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem 2003; 278: 6411–6419.
Acknowledgements
This work was supported by grants from: AIRC, Italian MIUR Cofin 2001 and 2002, FIRB 2001, Selected Topics Research Fund from Bologna University, CARISBO Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cappellini, A., Tabellini, G., Zweyer, M. et al. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27Kip1 and control of cyclin D1 expression. Leukemia 17, 2157–2167 (2003). https://doi.org/10.1038/sj.leu.2403111
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403111
- Springer Nature Limited
Keywords
This article is cited by
-
Outside-in integrin signalling regulates haematopoietic stem cell function via Periostin-Itgav axis
Nature Communications (2016)
-
“Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’
Blood Cancer Journal (2013)
-
Mosaiktrisomie 8p11.21q11.21 als Prädisposition für myeloische Leukämien
Medizinische Genetik (2012)
-
Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen
BMC Cancer (2010)
-
FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol
Molecular and Cellular Biochemistry (2010)